MedPath

Implantation of Markers for the Radiotherapy of Lung Cancer Patients

Phase 1
Terminated
Conditions
Lung Cancer
Interventions
Radiation: radiation therapy treatment planning/simulation
Procedure: implanted fiducial-based imaging
Registration Number
NCT00856427
Lead Sponsor
Virginia Commonwealth University
Brief Summary

This clinical trial studies imaging markers in planning radiation therapy in patients with lung cancer. Implanting markers in the tumor that can be seen using imaging procedures during radiation therapy may allow x-rays to be sent directly to the tumor and cause less damage to normal tissue.

Detailed Description

OBJECTIVES:

* To acquire experience in the marker implantation process for mediastinal lymph nodes and primary lung tumors in patients with stage I-IIIB non-small cell lung cancer.

* To characterize the potential side effects involved in the use of markers in these patients.

* To analyze the positional stability of lung markers in these patients over a radiotherapy series.

* To acquire experience in the use of markers for treatment planning and radiotherapy in these patients.

OUTLINE: Patients undergo implantation of ≥ 1 small radio-opaque Visicoil™ marker into or close to the primary lesion and affected lymph nodes by bronchoscopy. Patients then undergo x-rays to document marker location, detect potentially dropped markers, and diagnose operation-related side effects (i.e., pneumothorax). After marker implantation, patients undergo stereotactic or conventionally fractionated radiotherapy for 30-33 daily fractions.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
6
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Diagnosticradiation therapy treatment planning/simulationPatients undergo implantation of radio-opaque markers into the primary lesion and affected lymph nodes by bronchoscopy. Patients then undergo routine 4D CT, 4D CBCT, fluoroscopy, and x-ray imaging during standard stereotactic radiation therapy (early stage tumors) or conventionally fractionated radiation therapy (advanced stage tumors).
Diagnosticimplanted fiducial-based imagingPatients undergo implantation of radio-opaque markers into the primary lesion and affected lymph nodes by bronchoscopy. Patients then undergo routine 4D CT, 4D CBCT, fluoroscopy, and x-ray imaging during standard stereotactic radiation therapy (early stage tumors) or conventionally fractionated radiation therapy (advanced stage tumors).
Primary Outcome Measures
NameTimeMethod
Positional reliability of markersUp to 5 years
Number of dropped markersup to 5 years
Visibility of markers on CT and x-raysup to 5 years
Marker misplacementsup to 5 years
Implantation-related side effectsup to 5 years
Usability for patient treatmentup to 5 years
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Virginia Commonwealth University Massey Cancer Center

🇺🇸

Richmond, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath